The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Peripheral T Cell Lymphomas Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market.

Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report:

• Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years. 
• Peripheral T Cell Lymphomas companies working in the treatment market are Applied Therapeutic, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment 
• Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years.  
• In July 2023, In a phase 2 trial analysis, the use of the tetravalent, bispecific antibody construct AFM13 was thought to be related to clinical efficacy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). The findings of the study were recently presented by Won Seog Kim, MD, PhD, of the Samsung Medical Centre in Seoul, Korea, and associates at the International Conference on Malignant Lymphoma 2023.
• In July 2023, An early analysis of a phase 2a trial (NCT05140382) using the CDK9 inhibitor AZD4573 as a single drug resulted in clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), according to research presented at the 17th Annual International Conference on Malignant Lymphoma
• In June 2023, Viracta Therapeutics, a clinical-stage biotechnology company, has initiated a pivotal Phase 1/2 clinical trial called NAVAL-1 for its lead product candidate, nanatinostat (VRx-3996), in combination with the antiviral valganciclovir. The trial aims to evaluate the safety and efficacy of this combination therapy in patients with Epstein-Barr virus-positive (EBV+) lymphomas and solid tumors. NAVAL-1 is designed to enroll both adults and children and will be conducted at multiple sites globally. The trial’s initiation marks a significant milestone for Viracta Therapeutics as they work towards developing an effective treatment for patients suffering from EBV-associated cancers, which currently have limited therapeutic options. 
• In November 2022, In order to jointly develop, produce, and market a combination therapy using Artiva Biotherapeutics Inc.’s AB-101 allogeneic NK cell product candidate and Affimed’s innate cell engager (ICE) AFM13, the two companies have announced a new strategic partnership. Affimed asked the FDA for input on the clinical trial design in relapsed/refractory (r/r) Hodgkin lymphoma (HL) with an exploratory arm evaluating the combination in r/r CD30-positive peripheral T-cell lymphoma (PTCL), as well as a potential route to registration, in a pre-IND meeting request for the co-administration of AFM13 and AB-101. In response, the FDA instructed people to offer feedback by Q1 2023.
• MT-101 is being developed to treat CD5-expressing T-cell lymphomas that have relapsed or are otherwise resistant to treatment. Myeloid Therapeutics reported in October 2022 that MT-101 had been given Fast Track Designation by the US Food and Drug Administration for use in patients with refractory or relapsed CD5+ peripheral T cell lymphoma. A Phase II trial will start as soon as Myeloid determines the suggested Phase II dose to support registration in this patient population.
• In April 2021, In order to evaluate Copiktra’s efficacy in treating individuals with relapsed or refractory PTCL, Secura Bio reported that enrolment of 101 patients into the PRIMO study has been completed. A significant step in the ongoing development of Copiktra to treat T-cell lymphomas, a disease category for which it is not currently recommended, is the completion of trial enrolment.

Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight

Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include:

• AT-104: Applied Therapeutic
• Auto 5: Autolus
• AK 104: Akeso Biopharma
• Tolinapant: Astex Pharmaceuticals
• Duvelisib: Secura Bio
• Lacutamab: Innate Pharma
• AZD 4205: Dizal Pharmaceutical
• Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
• HBI-8000: HUYA Bioscience International

Peripheral T Cell Lymphomas Route of Administration

Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Intra-tumoral
• Molecule Type

Peripheral T Cell Lymphomas Molecule Type

Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as

• Monoclonal antibodies
• Immunoglobulins
• Small molecules
• Pyrimidines
• Proteins and Peptides
• Product Type

Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment

• Peripheral T Cell Lymphomas Assessment by Product Type
• Peripheral T Cell Lymphomas By Stage and Product Type
• Peripheral T Cell Lymphomas Assessment by Route of Administration
• Peripheral T Cell Lymphomas By Stage and Route of Administration
• Peripheral T Cell Lymphomas Assessment by Molecule Type
• Peripheral T Cell Lymphomas by Stage and Molecule Type

DelveInsight’s Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies

Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include:

Key companies developing therapies for Peripheral T Cell Lymphomas are – Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, iCell Gene Therapeutics, Tessa Therapeutics, Merck Sharp & Dohme, Rhizen Pharmaceuticals, Bayer, Dialectic Therapeutics, and others.

Peripheral T Cell Lymphomas Pipeline Analysis:

The Peripheral T Cell Lymphomas pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment.
• Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies

Peripheral T Cell Lymphomas Pipeline Market Drivers

• Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market.

Peripheral T Cell Lymphomas Pipeline Market Barriers

• However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth.

Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight    

• Coverage: Global
• Key Peripheral T Cell Lymphomas Companies: Applied Therapeutic, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others
• Key Peripheral T Cell Lymphomas Therapies: AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others
• Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies
• Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers 

Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials

Table of Contents 

1. Peripheral T Cell Lymphomas Report Introduction

2. Peripheral T Cell Lymphomas Executive Summary

3. Peripheral T Cell Lymphomas Overview

4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment

5. Peripheral T Cell Lymphomas Pipeline Therapeutics

6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III)

7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II)

8. Peripheral T Cell Lymphomas Early Stage Products (Phase I)

9. Peripheral T Cell Lymphomas Preclinical Stage Products

10. Peripheral T Cell Lymphomas Therapeutics Assessment

11. Peripheral T Cell Lymphomas Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peripheral T Cell Lymphomas Key Companies

14. Peripheral T Cell Lymphomas Key Products

15. Peripheral T Cell Lymphomas Unmet Needs

16 . Peripheral T Cell Lymphomas Market Drivers and Barriers

17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion

18. Peripheral T Cell Lymphomas Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services